HS
RLMD icon

HighVista Strategies’s Relmada Therapeutics RLMD Stock Holding History

HighVista Strategies’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26,299
Closed -$91.8K – 130
2022
Q4 		$91.8K Sell
26,299
-3,764
-13% -$33.1K 0.05% 105
2022
Q3 		$1.11M Buy
30,063
+570
+2% +$15.8K 0.64% 39
2022
Q2 		$560K Buy
29,493
+8,112
+38% +$177K 0.34% 72
2022
Q1 		$577K Buy
+21,381
New +$442K 0.37% 68
2021
Q1 		– Sell
-22,450
Closed -$720K – 137
2020
Q4 		$720K Buy
22,450
+9,885
+79% +$340K 0.46% 52
2020
Q3 		$473K Buy
12,565
+2,872
+30% +$111K 0.34% 55
2020
Q2 		$434K Buy
+9,693
New +$410K 0.36% 38

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighVista Strategies's RLMD Position: Q1 2023 in Review

HighVista Strategies sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 26,299 shares — an estimated $91.8K sold.

HighVista Strategies first reported a position in RLMD in Q2 2020 and held it in 7 quarters. The position peaked at $1.11M in Q3 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • HighVista Strategies reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • HighVista Strategies sold 26,299 Relmada Therapeutics shares in Q1 2023, an estimated $91.8K.
  • HighVista Strategies first reported a position in Relmada Therapeutics in Q2 2020 and held it in 7 quarters.
  • HighVista Strategies's Relmada Therapeutics position peaked at $1.11M in Q3 2022.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on HighVista Strategies's 13F filing for Q1 2023, filed 15 May 2023.